Circulating tumor DNA

There's always toxicity associated with some of these drugs.

So maybe we'll be able to learn more, stop the maintenance therapy earlier, maybe incorporate ctDNA into how long the maintenance should be.

But I think that's another finding in this study that we have to take a closer look on as far as duration of therapy.

That's really a great point.

And none of the biomarkers really directed towards either TDXD or Mervituximab as a useful next line of therapy in platinum-resistant disease.

So she started and is tolerating treatment well.

And we have early signs of decreasing CA125 and ctDNA dropping.

So encouraging.

There's always toxicity associated with some of these drugs.

So maybe we'll be able to learn more, stop the maintenance therapy earlier, maybe incorporate ctDNA into how long the maintenance should be.

But I think that's another finding in this study that we have to take a closer look on as far as duration of therapy.

That's really a great point.

And none of the biomarkers really directed towards either TDXD or Mervituximab as a useful next line of therapy in platinum-resistant disease.

So she started and is tolerating treatment well.

And we have early signs of decreasing CA125 and ctDNA dropping.

So encouraging.

And so she actually went through quite a bit more than a lot of patients do as far as getting chemotherapy afterwards.

So we now use that ongoing, that CT DNA or circulating tumor DNA to look and see whether there is any signs of cells or circulating tumor genetic material that's in her now or moving forward.

And we used it to determine when or how long she needed treatment afterwards as well.

So January 24, she comes in your office.

Any questions for the faculty?

If I am stopping all his anti-cancer therapies, can I utilize ctDNA to monitor his disease burden in the meanwhile? What are your top process when starting someone with type 2 diabetes on EnfortMap Vedotin? Whether you take into account if they are on insulin or not, or their A1c level to start EnfortMap Vedotin? For this gentleman with grade 3 pneumonitis, we didn't really think that re-challenge was possible, especially he required high-dose corticosteroid for a prolonged amount of time.

But in general, how do you approach to pneumonitis in bladder cancer population? If you could talk about your general approach based on grading of the pneumonitis and the impact on whether to re-challenge for what specific scenarios?

Any comments on the case? And also, whether it's clear or maybe there's some other reason that the pneumonitis is from the PEMBRO, could it have been from the infortimab also?

So when they come to us, You know, the question that always comes up and patients are asking us is, when did that happen? Could we have prevented this? Was it missed? And so it's still a question of the timing, especially since these patients only undergo cystoscopies and urine cytology.

Maybe the ctDNA story will change that.

Maybe if we start getting more and more testing, we'll catch those that are developing or are prone to develop oligometastatic or full-blown metastatic disease.

But again, it's not uncommon, at least in a specific TU oncology clinic.

And we don't, we are not stopping treatment.

The trial does not require to stop treatment.

We follow the ctDNA since that came up.

And, you know, it's a tough call to make, to stop if there is no toxicity.

Any questions for the faculty?

If I am stopping all his anti-cancer therapies, can I utilize ctDNA to monitor his disease burden in the meanwhile? What are your top process when starting someone with type 2 diabetes on EnfortMap Vedotin? Whether you take into account if they are on insulin or not, or their A1c level to start EnfortMap Vedotin? For this gentleman with grade 3 pneumonitis, we didn't really think that re-challenge was possible, especially he required high-dose corticosteroid for a prolonged amount of time.

But in general, how do you approach pneumonitis in bladder cancer population? If you could talk about your general approach based on grading of the pneumonitis and the impact on whether to re-challenge for what specific scenarios?

Any comments on the case? And also, whether it's clear, or maybe there's some other reason that the pneumonitis is from the PEMBRO, could it have been from the Enfortimab also?

Any questions for the faculty?

If I am stopping all his anticancer therapies, can I utilize ctDNA to monitor his disease burden in the meanwhile? What are your top process when starting someone with type 2 diabetes on enfortumab vedotin, whether you take into account if they are on insulin or not, or their A1C level to start enfortumab vedotin? For this gentleman with grade three pneumonitis, we didn't really think that a re-challenge was possible, especially he required high-dose corticosteroid for a prolonged amount of time.

But in general, how do you approach to pneumonitis in bladder cancer population? If you could talk about your general approach based on grading of the pneumonitis and the impact on whether to re-challenge for what specific scenarios.

Any comments on the case? And also, whether it's clear or maybe there's some other reason that the pneumonitis is from the pembro.